Clinical Trial Update: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update evaluates the combination of 7-Hydroxystaurosporine and Irinotecan Hydrochloride in patients with metastatic or unresectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Carcinoma of the Appendix
• Colon Cancer
• Liver Cancer
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• 7-hydroxystaurosporine (7-hydroxystaurosporine)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Status: COMPLETED